As of November 6, 2026, IO Biotech, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on March 31, 2026 (Form 8-K, March 31, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like IO Biotech, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
IO Biotech, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-03-31. Every row below is cited to the filing it comes from, and this page adds each new change as IO Biotech, Inc. files it.
Layoffs on record: 2 filings or notices, latest 2026-01-30 (layoff filings and notices).
Also on the record for IO Biotech, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| June 2, 2026 | Stake report, Schedule 13D/A, by Lundbeckfond Invest A/S | 27.4% of the class | 5%+ stakes | Source |
| May 20, 2026 | Stake report, Schedule 13G/A, by Chernett Jorey | — | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Point72 Asset Management, L.P. | — | 5%+ stakes | Source |
| April 6, 2026 | Stake report, Schedule 13G/A, by HBM Healthcare Investments (Cayman) Ltd. | 3.3% of the class | 5%+ stakes | Source |
| February 13, 2026 | Stake report, Schedule 13G/A, by Chernett Jorey | 6.3% of the class | 5%+ stakes | Source |
| February 6, 2026 | Stake report, Schedule 13G, by Point72 Asset Management, L.P. | 5.6% of the class | 5%+ stakes | Source |
| January 23, 2026 | Stake report, Schedule 13D/A, by Novo Holdings A/S | 3.3% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by Vivo Opportunity, LLC | 4.6% of the class | 5%+ stakes | Source |
| November 5, 2025 | Stake report, Schedule 13G, by Chernett Jorey | 5.3% of the class | 5%+ stakes | Source |
| August 19, 2025 | Stake report, Schedule 13D/A, by Novo Holdings A/S | 7.3% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs IO Biotech, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on IO Biotech, Inc. and the records around it.
IO Biotech, Inc. elsewhere on the record
- 5%+ stake filings Jun 2026
- Layoff notices Jan 2026
- Bankruptcy record
Companies that share a holder
- HBM Healthcare Investments (Cayman) Ltd. also filed stake reports on 7 other companies: Chemomab Therapeutics Ltd. (Sep 2026), ALX ONCOLOGY HOLDINGS INC (May 2026), Upstream Bio, Inc. (Nov 2025)
- Novo Holdings A/S also filed stake reports on 11 other companies: Avalyn Pharma Inc. (Aug 2026), Hemab Therapeutics Holdings, Inc. (Aug 2026), Obsidian Therapeutics, Inc. (Aug 2026)
- Chernett Jorey also filed stake reports on 16 other companies: CVRx, Inc. (Oct 2026), WW INTERNATIONAL, INC. (Aug 2026), Neuronetics, Inc. (Aug 2026)
Watch IO Biotech, Inc.
Get an email when IO Biotech, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on IO Biotech, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on IO Biotech, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on IO Biotech, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
12 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-03-31 | Reported | not named in the filing | 8-K, 2026-03-31 |
New leaders reset buying decisions — get the Full Report on IO Biotech, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at IO Biotech, Inc., with the record behind each one.
Find candidates like senior executive at IO Biotech, Inc.Every change, in the filing's words
Reported
Departure of Directors Concurrently with the Petition, on March 31, 2026, each member of the Company's board of directors, Peter Hirth, Helen Collins, Christian Elling, Kathleen Glaub, Heidi Hunter and David Smith, resigned from the Board of Directors of the Company and all of its committees.
- Each of the directors resigned because of the Company's filing of the Petition, which effectively eliminated the powers of the Company's Board of Directors.
- The resignations were not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.
- Following the resignations, the Company has no members serving on its Board of Directors.
- Departure of Officers Concurrently with the Petition, on March 31, 2026, the Company terminated all employees and officers without cause, including Mai-Britt Zocca, Chief Executive Officer, and Amy Sullivan, Chief Financial Officer and Chief Accounting Officer.
- These terminations were due to the filing of the Petition, which effectively eliminated the powers and roles of these officers.
Tools for this story
Each opens in a new tab, filled in for IO Biotech, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.